Neutrophil-specific gain-of-function mutations in Nlrp3 promote development of cryopyrin-associated periodic syndrome.
Adolescent
Adult
Aged, 80 and over
Animals
Cryopyrin-Associated Periodic Syndromes
/ genetics
Female
Gain of Function Mutation
Humans
Interleukin-1beta
/ metabolism
Male
Mast Cells
/ pathology
Mice, Transgenic
Middle Aged
NLR Family, Pyrin Domain-Containing 3 Protein
/ genetics
Neutrophils
/ pathology
Journal
The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R
Informations de publication
Date de publication:
04 10 2021
04 10 2021
Historique:
received:
10
07
2020
revised:
10
06
2021
accepted:
30
07
2021
entrez:
3
9
2021
pubmed:
4
9
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Gain-of-function mutations in NLRP3 are responsible for a spectrum of autoinflammatory diseases collectively referred to as "cryopyrin-associated periodic syndromes" (CAPS). Treatment of CAPS patients with IL-1-targeted therapies is effective, confirming a central pathogenic role for IL-1β. However, the specific myeloid cell population(s) exhibiting inflammasome activity and sustained IL-1β production in CAPS remains elusive. Previous reports suggested an important role for mast cells (MCs) in this process. Here, we report that, in mice, gain-of-function mutations in Nlrp3 restricted to neutrophils, and to a lesser extent macrophages/dendritic cells, but not MCs, are sufficient to trigger severe CAPS. Furthermore, in patients with clinically established CAPS, we show that skin-infiltrating neutrophils represent a substantial biological source of IL-1β. Together, our data indicate that neutrophils, rather than MCs, can represent the main cellular drivers of CAPS pathology.
Identifiants
pubmed: 34477811
pii: 212620
doi: 10.1084/jem.20201466
pmc: PMC8421266
pii:
doi:
Substances chimiques
IL1B protein, human
0
Interleukin-1beta
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
NLRP3 protein, human
0
Nlrp3 protein, mouse
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : U19 AI104209
Pays : United States
Organisme : European Research Council
ID : ERC-2013-CoG 616050
Pays : International
Organisme : European Research Council
ID : 801823
Pays : International
Organisme : NIAID NIH HHS
ID : R01 AI125567
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR067145
Pays : United States
Organisme : NIAID NIH HHS
ID : K99 AI110645
Pays : United States
Organisme : NIH HHS
ID : K99 AI110645
Pays : United States
Organisme : NIH HHS
ID : R01 AI132494
Pays : United States
Organisme : NIH HHS
ID : R01 DK113592
Pays : United States
Organisme : NIH HHS
ID : R01 AI15586901
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK113592
Pays : United States
Organisme : European Research Council
ID : 802041
Pays : International
Organisme : NIAID NIH HHS
ID : R01 AI132494
Pays : United States
Informations de copyright
© 2021 Stackowicz et al.
Déclaration de conflit d'intérêts
Disclosures: L. Broderick reports "other" from Novartis, Inc. outside the submitted work. H.M. Hoffman reports "other" from Novartis, IFM, AB2Bio, Takeda, and Zomagen; and grants from Jecure outside the submitted work. No other disclosures were reported.
Références
Arthritis Rheum. 2008 Aug;58(8):2443-52
pubmed: 18668535
Arthritis Rheum. 2007 Apr;56(4):1273-1285
pubmed: 17393462
Clin Ther. 2012 Oct;34(10):2091-103
pubmed: 23031624
J Immunol Methods. 2014 Jun;408:89-100
pubmed: 24857755
Blood. 2004 Apr 1;103(7):2809-15
pubmed: 14630794
J Exp Med. 2009 May 11;206(5):1037-46
pubmed: 19364881
J Biol Chem. 2004 May 21;279(21):21924-8
pubmed: 15020601
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2946-51
pubmed: 23382184
J Allergy Clin Immunol. 2016 Jul;138(1):3-14
pubmed: 27373321
Nat Genet. 2001 Nov;29(3):301-5
pubmed: 11687797
J Clin Invest. 2020 Sep 1;130(9):4561-4573
pubmed: 32716363
J Allergy Clin Immunol. 2020 Apr;145(4):1254-1261
pubmed: 31816408
J Exp Med. 2017 May 1;214(5):1249-1258
pubmed: 28385925
Immunity. 2011 Jun 24;34(6):973-84
pubmed: 21703544
Nature. 2006 Mar 9;440(7081):237-41
pubmed: 16407889
Arthritis Rheum. 2002 Dec;46(12):3340-8
pubmed: 12483741
J Clin Invest. 2013 Nov;123(11):4695-705
pubmed: 24084736
Sci Immunol. 2018 Dec 7;3(30):
pubmed: 30530726
Sci Immunol. 2018 Aug 24;3(26):
pubmed: 30143555
Cell. 2004 Oct 29;119(3):431-43
pubmed: 15507213
Immunity. 2009 Jun 19;30(6):860-74
pubmed: 19501001
Trends Immunol. 2012 Dec;33(12):613-25
pubmed: 23127755
J Immunol. 2008 Sep 15;181(6):3755-9
pubmed: 18768827
J Allergy Clin Immunol. 2017 Aug;140(2):335-348
pubmed: 28780941
Immunity. 2009 Jun 19;30(6):875-87
pubmed: 19501000
N Engl J Med. 2009 Jun 4;360(23):2416-25
pubmed: 19494217
Cell Mol Immunol. 2016 Mar;13(2):148-59
pubmed: 26549800
J Clin Invest. 2017 Dec 1;127(12):4488-4497
pubmed: 29130929
J Clin Invest. 2016 Oct 3;126(10):3981-3998
pubmed: 27643442
Immunity. 2004 Mar;20(3):319-25
pubmed: 15030775
Nat Rev Immunol. 2010 Mar;10(3):210-5
pubmed: 20168318
J Immunol. 1980 Jun;124(6):2728-37
pubmed: 7373045
Nat Immunol. 2008 Oct;9(10):1091-4
pubmed: 18800157
Mol Cell. 2002 Aug;10(2):417-26
pubmed: 12191486
Nat Rev Immunol. 2013 Jun;13(6):397-411
pubmed: 23702978
Lancet. 2004 Nov 13-19;364(9447):1779-85
pubmed: 15541451
Front Pharmacol. 2017 May 22;8:278
pubmed: 28588486
J Allergy Clin Immunol. 2007 Sep;120(3):506-15; quiz 516-7
pubmed: 17765751
Blood. 2011 Dec 22;118(26):6930-8
pubmed: 22001390
Front Cell Infect Microbiol. 2017 Dec 11;7:507
pubmed: 29322034
Immunity. 2012 Jul 27;37(1):85-95
pubmed: 22819042
J Allergy Clin Immunol. 2001 Oct;108(4):615-20
pubmed: 11590390
Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):870-5
pubmed: 19139407
Nat Rev Drug Discov. 2020 Apr;19(4):253-275
pubmed: 31969717
Sci Immunol. 2018 Aug 24;3(26):
pubmed: 30143554